Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q4 FY22 results · Jan–Mar 2022

Jubilant Pharmova reported revenue from operations of ₹1,514.44 crore (down 4.1% from Q4 FY21) and net profit of ₹59.09 crore (down 72.3% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	1,514.44	1,579.78	−4.1%	1,310.53	+15.6%
Other income	10.13	6.69	+51.4%	5.91	+71.4%
Total income	1,524.57	1,586.47	−3.9%	1,316.44	+15.8%
Profit before share of associates & JVs and tax	104.33	241.39	−56.8%	70.20	+48.6%
Share of profit/(loss) of associates & JVs	1.34	14.35		0.03
Net profit for the period	59.09	213.65	−72.3%	50.80	+16.3%
Attributable to shareholders of the company	59.55	213.90	−72.2%	50.99	+16.8%
EPS, basic (₹)	3.74	13.43	−72.2%	3.20	+16.9%
Net margin (%)	3.9	13.5		3.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY22	Q4 FY21	YoY	Q3 FY22	QoQ
Revenue from operations	28.79	365.86	−92.1%	18.67	+54.2%
Other income	7.10	13.80	−48.6%	8.58	−17.2%
Total income	35.89	379.66	−90.5%	27.25	+31.7%
Profit before tax	(4.14)	45.87	Turned loss	(6.22)	Loss narrowed
Net profit for the period	(3.11)	35.16	Turned loss	(5.34)	Loss narrowed
EPS, basic (₹)	(0.19)	2.21	Turned loss	(0.34)	Loss narrowed
Net margin (%)	-10.8	9.6		-28.6

Consolidated

Filed with BSE: 28 May 2022, 16:01 IST
Board meeting: 27 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 28 May 2022, 16:01 IST
Board meeting: 27 May 2022
Period: 01 Jan 2022 to 31 Mar 2022
Review status: Audited
Source: XBRL filing on BSE